Clinical Trial Update: Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the impact of aclidinium/formoterol on lung hyperinflation, exercise capacity, and physical activity in moderate to severe COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• aclidinium/formoterol

Snippet

Sponsor: AstraZeneca | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2018-10-09